DYDan Yao

Dan Yao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dan Yao has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoying Huang

    Key Laboratory of Heart and Lung, Division of Pulmonary Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    6 shared publications
  • Yichen Liu

    Division of Pulmonary Medicine, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China

    3 shared publications
  • Lanlan Song

    Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine Wenzhou Key Laboratory of Heart and Lung Wenzhou PR China

    2 shared publications
  • Mengsi Cai

    Division of Pulmonary Medicine, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China

    2 shared publications
  • Beihui Xue

    Division of Pulmonary Medicine, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China

    1 shared publication
  • Chang Yu

    Intervention Department, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China

    1 shared publication

Latest Publications

  • Open Access

    A weakly supervised deep learning-based recurrence prediction and risk stratification of lung adenocarcinoma from pathology whole-slide images

    by Beihui Xue, Yichen Liu, Mengsi Cai, Liudan Gu, Jiayu Bai, Liping Yao, Jianmin Li, Liangxing Wang, Xiaoying Huang, Dan Yao

    Accurate prediction of postoperative recurrence in lung adenocarcinoma (LUAD) is essential for guiding clinical decision-making and improving patient outcomes. Although various predictive models have been developed, most rely on complex genomic analyses and high-dimensional clinical data. The complexity of these approaches substantially limits their feasibility for routine clinical use. To address this clinical challenge, this study aims to predict postoperative recurrence using routinely available hematoxylin and eosin (H&E)-stained images and characterize the associated biological features. A total of 329 patients who underwent curative resection at the First Affiliated Hospital of Wenzhou Medical University (FHWMU) were retrospectively enrolled and randomly assigned to training and internal validation cohorts in a 7:3 ratio. An independent external validation cohort comprising 70 patients from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) was included. Three patch-level feature extractors (Inception_V3, ResNet18, and DenseNet121) were evaluated within a weakly supervised multiple-instance learning (MIL) framework incorporating automated region-of-interest (ROI) detection on segmented whole-slide images (WSIs). Model performance was assessed using the area under the receiver operating characteristic curve (AUC), Kaplan-Meier (KM) survival analysis, and multivariable Cox proportional hazards regression. Transcriptomic profiling and gene set enrichment analysis (GSEA) were conducted to investigate biological differences between risk groups. The model achieved AUCs of 0.923 in the training cohort, 0.891 in the internal validation cohort, and 0.847 in the external validation cohort. The model effectively stratified patients into high- and low-risk groups with significantly different recurrence-free survival (RFS) across all cohorts (all P < 0.001) and retained prognostic value within AJCC stages I-III. Transcriptomic analyses revealed consistent enrichment of cell cycle-related pathways and neutrophil extracellular trap (NET) formation in high-risk patients across both institutional and CPTAC cohorts, aligning with distinct biological profiles of the model-derived risk stratification. This weakly supervised deep learning framework enables accurate and externally validated prediction of postoperative recurrence in LUAD using routinely available histopathological images, and integration of histopathological features with molecular analyses enhances biological interpretability. This work provides a clinically accessible and cost-effective tool for postoperative risk assessment in LUAD patients.

  • Open Access

    The landscape of MET alterations in non-small cell lung cancer in Southeastern China: a real-world study

    by Sisi Zheng, Ziyi Zuo, Rixu Lin, Xiaoxiao Zhang, Lujie Huang, Mengsi Cai, Yifan Ye, Dan Yao, Xiaoying Huang

    Background: MET is a key driver in NSCLC yet comprehensive, multi-subtype real-world data in China are lacking. Methods: Real-world data were collected from MET-altered NSCLC patients diagnosed at a comprehensive hospital in southeastern China (July 2021–December 2023). Four subgroups were analyzed: MET IHC-Positive, MET Amplification, MET Exon 14 skipping, and MET Other Mutations. Demographics, risk factors, comorbidities, pathology, co-mutation, and treatment patterns were compared. With 2-year follow-up, survival outcomes and MET-TKI benefit were analyzed. Results: Among 574 patients: MET IHC-Pos (81.4%), MET-Amp (11.0%), MET-Ex14 (4.70%), and Others (2.96%). Patients were predominantly elderly, male, with > 40% smoking history and > 35% hypertension. Pathological specimens were mainly obtained via bronchoscopy or percutaneous lung puncture. Adenocarcinoma dominated all subtypes (> 70%), increasing with IHC intensity in MET IHC-Pos ( p < 0.05). MET-Amp showed the highest advanced stage (87.3%), bone (36.5%) and brain metastasis (17.5%). TP53 was the most common co-mutation (20.7%–25.0%). Targeted therapy predominated (Line 1st: 54.6%, Line 2nd: 38.9%), followed by chemotherapy plus immunotherapy. The 24-month OS was lower in MET-Amp (44.4%) and MET-Ex14 (48.1%) than in MET IHC-Pos (57.2%) and Others (58.8%). The 24-month OS (MET-TKI treated vs. untreated) was: 69.2% vs. 38.5% (MET IHC-Pos 2 + /3 +), 71.4% vs. 25.0% (MET-Ex14), and 47.4% vs. 42.9% (MET-Amp). Conclusions: MET alterations occur predominantly in the elderly, males, and smokers. MET-Ex14 shows driver-dependent characteristics with clear MET-TKI benefit. MET-Amp presents the most aggressive phenotype. MET IHC-Pos predominates (> 80%) with heterogeneity; the 2 + /3 + may benefit from MET-TKI. These findings inform subtype-based management of MET-altered NSCLC in southeastern China.

  • Open Access

    Endoplasmic reticulum stress and the unfolded protein response in lung diseases: molecular pathways and therapeutic interventions

    by Lanlan Song, Yichen Liu, Chen Xu, Yaochen Zhang, Kaiming Xu, Dan Yao, Xiaoying Huang

    Endoplasmic reticulum stress (ERS) occurs when the protein‐folding capacity of the endoplasmic reticulum (ER) is overwhelmed, triggering the unfolded protein response (UPR) to restore homeostasis. However, severe or persistent ERS can shift the UPR toward pro‐inflammatory, apoptotic, and fibrotic signaling, thereby exacerbating tissue injury. The pathogenesis and progression of lung diseases, which involve highly heterogeneous cell populations, are significantly influenced by these mechanisms. Indeed, ERS and UPR activation are now recognized as central players in the pathophysiology of numerous lung diseases. This review examines the impact of dysregulated ERS/UPR signaling across different lung diseases, with a particular focus on its cell‐type‐specific effects and disease‐specific implications. Furthermore, we discuss emerging therapeutic strategies designed to modulate these pathways. A comprehensive understanding of the cell‐type‐specific outcomes of ERS/UPR is therefore crucial for developing targeted interventions to mitigate or reverse lung disease progression. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


  • Open Access

    Immunotherapy and the Sequence Relative to Survival Outcomes in SCLC: Analysis of the National Cancer Database

    by Dan Yao, Yinting Liu, Wenyao Yu, Sisi Zheng, Lujie Huang, Mengsi Cai, Yan Zhuang, Youwen He, Xiaoying Huang

    Background: SCLC remains an aggressive malignancy with limited therapeutic progress over the past few decades. It remains unclear how the sequence of immunotherapy initiation influences overall survival (OS) in SCLC; we performed a population-based analysis using NCDB to evaluate its association with survival. Methods: SCLC patients in NCDB from 2016 to 2021 were identified to evaluate the impact of immunotherapy on OS. Among ES-SCLC patients, we conducted subsequent analyses to clarify the relationship between the sequence of immunotherapy initiation and OS in the context of chemotherapy and CRT. Results: Among 69,820 eligible patients, 9242 received CRT plus immunotherapy (CRT + IO), and 11,755 received chemotherapy plus immunotherapy (Chemo + IO). In the overall population, adding immunotherapy to chemotherapy or CRT was associated with modestly improved survival. In ES-SCLC, immunotherapy was associated with longer survival in both the Chemo and CRT cohort, while the addition of immunotherapy did not confer benefits in limited-stage SCLC (LS-SCLC). Within the ES-SCLC Chemo + IO cohort, altering the initiated immunotherapy interval (0–90 days) did not show any meaningful difference in survival. By contrast, in the CRT + IO cohort, survival showed benefit in a time-dependent pattern: patients who initiated immunotherapy within 4–7 days after CRT had a trend of survival, which was consistent with the proposed immune activation window. Conclusions: This real-world analysis suggests that immunotherapy was associated with longer survival in ES-SCLC, CRT + IO is associated with improved OS, with a more obvious survival benefit when immunotherapy is initiated within 4–7 days after CRT. These findings hint at the potential importance of immunotherapy initiation sequence and warrant further prospective validation.

  • Open Access

    A comprehensive narrative review of Epimedium and its bioactive compounds in respiratory diseases

    by Lanlan Song, Changyu Lei, Cheng Zheng, Yichen Liu, Jian Liu, Dan Yao, Xiaoying Huang


  • Open Access

    Icariside II alleviates lipopolysaccharide-induced acute lung injury by inhibiting lung epithelial inflammatory and immune responses mediated by neutrophil extracellular traps

    by Xiuchun Li, Yangyue Wang, Yuxin Chen, Ziyi Lu, Yihan Sun, Chuyue Zhong, Zhanghang Lv, Haofeng Pan, Jun Chen, Dan Yao, et al.